Outbreak of Hemolytic Uremic Syndrome Linked to Escherichia Coli of Serotype O104:H4 (SHU O104 CUB)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01406288|
Recruitment Status : Completed
First Posted : August 1, 2011
Last Update Posted : November 20, 2012
The Hemolytic Uremic Syndrome (HUS) in its typical form occurs after a food born infection with a shiga-toxin secreting bacteria, usually Escherichia coli of the O157H7 serotype. An outbreak of bloody diarrhea followed by HUS begun after a collective meal with 120 persons on June 8th, 2011 in Bègles, a city of Bordeaux urban area (CUB).
At least 9 patients, 8 adults and 1 child have been involved in this HUS outbreak, E. coli of the O104:H4 serotype being demonstrated in most patients. This outbreak is remarkable by its preponderance in adults and women, its aggressiveness with multiorgan involvement , i.e. the kidneys, brain, liver, pancreas, and skin.
Pathophysiology, prognosis, and treatment of typical HUS are poorly defined, particularly in adults who are usually not involved in typical E. coli O157H7 HUS.
The aim of the present study is to gain knowledge on these different aspects of the HUS, including response to therapy.
|Condition or disease||Intervention/treatment|
|Hemolytic-uremic Syndrome Escherichia Coli Infections||Other: HUS standard coverage care (including in ICU)|
|Study Type :||Observational|
|Actual Enrollment :||9 participants|
|Official Title:||Outbreak of Hemolytic Uremic Syndrome Linked to Escherichia Coli of Serotype O104:H4 in Bordeaux Urban Area, June 2011: Evaluation of Diagnostic, Prognostic and Pathophysiological Data|
|Study Start Date :||July 2011|
|Primary Completion Date :||March 2012|
|Study Completion Date :||March 2012|
|HUS epidemy in Bordeaux, E. coli of the O104H4 serotype||
Other: HUS standard coverage care (including in ICU)
HUS standard coverage care : plasmaphereses - eculizumab - Immunoadsorption
- Improve scientific knowledge on epidemic HUS in the context of an outbreak of E. coli O104:H4 HUS in the town of Bègles, urban area of Bordeaux, France [ Time Frame: during patient hospitalization ]This is an observational propspective study in which all data will be collected on all pertinent aspects of disease, including therapeutic regimens.
- evaluate efficiency of therapeutic and diagnostic strategies [ Time Frame: during patient hospitalization ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01406288
|Service de Néphrologie, transplantation dialyse - Hôpital Pellegrin|
|Bordeaux, France, 33076|
|Study Director:||christian COMBE, MD||UH Bordeaux|
|Principal Investigator:||Christian COMBE, MD||UH Bordeaux|